Conditions: Epithelial Ovarian Cancer Primary Peritoneal Carcinoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 48
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.

Detailed description:

Arms:

Interventions: intervention 1: Bevacizumab intervention 2: Abraxane
Intervention descriptions: intervention 1: Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle. intervention 2: Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Protocol document: